Čájehuvvojit 1 - 6 oktiibuot 6 bohtosis ohcui Flynt, E', ohcanáigi: 0,02s
Aiddostahte ozu
-
1
Reading iventory : for the classroom / Dahkki 449570 Flynt, E. Sutton, Cooter, Robert B.
Almmustuhtton 1998 -
2
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma Dahkki Amatangelo, M, Flynt, E, Stong, N, Ray, P, Van Oekelen, O, Wang, M, Ortiz, M, Maciag, P, Peluso, T, Parekh, S, van de Donk, NWCJ, Lonial, S, Thakurta, A
Almmustuhtton 2024Journal article -
3
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients Dahkki Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Salazar, MA, Fitzsimons, E, Estevez, MO, Towfic, F, Flynt, E, Pierceall, WE, Yong, K, Vyas, P, Thakurta, A
Almmustuhtton 2021Conference item -
4
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma Dahkki Gooding, S, Ansari-Pour, N, Towfic, F, Ortiz Estévez, M, Chamberlain, PP, Tsai, K-T, Flynt, E, Hirst, M, Rozelle, D, Dhiman, P, Neri, P, Ramasamy, K, Bahlis, N, Vyas, P, Thakurta, A
Almmustuhtton 2020Journal article -
5
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma Dahkki Van Oekelen, O, Amatangelo, M, Guo, M, Upadhyaya, B, Cribbs, AP, Kelly, G, Patel, M, Kim-Schulze, S, Flynt, E, Lagana, A, Gooding, S, Merad, M, Jagganath, S, Pierceall, WE, Oppermann, U, Thakurta, A, Parekh, S
Almmustuhtton 2024Journal article -
6
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma Dahkki Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A
Almmustuhtton 2022Journal article